EUCTR2016-004572-21-GB进行中（未招募）1 期
Proof-of-concept study of BI 655130 add-on treatment in patients with mild-to-moderately active ulcerative colitis during TNF inhibitor therapy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- 18 – 75 years at screening and randomisation
- •- Diagnosis of ulcerative colitis =5 months prior to screening
- •- ReceivingTNFi treatment with doses unchanged for =4 months (infliximab) or =2 months (adalumimab and golimumab) prior to randomisation
- •- Mild or moderate disease activity, defined as total Mayo Score (MCS) (=10)
- •- Further criteria apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •- Prior use of more than one different TNF inhibitor or vedolizumab
- •- Extensive colonic resection
- •- Evidence of infection with C. difficile or other intestinal pathogen <28 days prior to screening
- •- Active or latent tuberculosis
- •- Further criteria apply
研究者
相似试验
招募中
1 期
A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and neck cancer or liver cancerPatients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular cJPRN-jRCT2031210650Tsunoda Toru150
进行中（未招募）
1 期
BI 655130 long-term treatment in patients with moderate-to-severe ulcerative colitisModerate-to-severely active ulcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-000334-35-NOBoehringer Ingelheim Norway KS79
撤回
2 期
An open label, long term safety trial of BI 655130 treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trialsUlcerative colitisNL-OMON48579Boehringer Ingelheim7
进行中（未招募）
1 期
BI 655130 long-term treatment in patients with moderate-to-severe ulcerative colitisModerate-to-severely active ulcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-000334-35-PLBoehringer Ingelheim RCV GmbH&Co. KG160
进行中（未招募）
1 期
BI 655130 long-term treatment in patients with moderate-to-severe ulcerative colitisModerate-to-severely active ulcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-000334-35-ESBoehringer Ingelheim España, S.A.160